EN DE
Watch Ikonisys SA for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ikonisys SA (ALIKO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Ikonisys SA stock €1.14, price €1.41, that is 19.1% below the price, quality 27 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR00140048X2

IS Ikonisys SA logo Thin data Nov 10, 2026

Ikonisys SA

ALIKO · PA
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Low debt
Revenue last quarter +23% vs. a year ago.
Expensive Growth (revenue 5y +69.3 %/yr in EUR)
Fair value €1.14 · Overvalued
Quality 27/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Ikonisys SA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.01 €1.15 Fair Value €1.14 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range €1.15 – €3.01 · fair‑value band €0.8600 – €1.43 · the €1.41 price screens above the €1.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Ikonisys in your weekly email

Every Wednesday you see whether Ikonisys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe.

Show moreShow less

It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution.

The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems.

In addition, it offers liquid biopsy/CTC bladder cancer detection and breast cancer early diagnostics products; CYTOfast vial solution for any type of cellular analysis; CYTOfast kit urine, a three day cytological urine test solution; CYTOfast PLUS, a liquid-phase processor that prepares thin-layer cytological samples from liquid-phase specimen; and Ikonisys intelligent application, a software designed to automatically quantify, qualify, and present cells for review and streamlining the diagnostic process.

Ikonisys S.A. was incorporated in 2021 and is headquartered in Paris, France.

Stock analysis

Ikonisys SA (ALIKO) currently trades at €1.41, while our estimate is €1.14, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.8600 (bear) to €1.43 (bull), the price of €1.41 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ikonisys SA reported revenue of €1.4M in FY2025 versus €365K in FY2021, a compound +39.6%/yr. Reported net income was −€4.2M in FY2025.

Key figures

Market cap €22.3M Micro · P/S ratio 13.7 · EPS (TTM) €−0.2900 · Return on equity −16.4% · Return on assets (EBIT) −10.3% (5-year average) · Operating margin −342% · Revenue (TTM) €1.6M · Revenue growth (YoY) +23.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −19%, ALIKO screens richer than that median.

Fair Value

Bear €0.8600 Fair Value €1.14 Bull €1.43
Price €1.41 · Downside -19.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 26
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+37.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
205.1% (2020) → −290.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALIKO screens overvalued: fair value 19% below the price. Compare with Abbott Laboratories, →

Compare Ikonisys SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −19.1% · Below median
Profitability
Return on assets −15.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.2% · Above median
Balance sheet
Debt / equity 0.07× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.17× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 13.60× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)97 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs ALIKO
DexCom, Inc DXCM $79.92 $89.18 +12% vs ALIKO
Stryker Corporation SYK $324.29 $358.30 +10% vs ALIKO
STERIS plc STE $257.12 $279.53 +9% vs ALIKO
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs ALIKO
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs ALIKO
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs ALIKO
Abbott Laboratories, ABT $110.46 $75.28 −32% vs ALIKO
Medtronic plc MDT $101.59 $65.61 −35% vs ALIKO
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs ALIKO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ikonisys SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ikonisys SA Fair Value". https://www.fairvalue-calculator.com/stock/ALIKO

Frequently asked questions

Is Ikonisys SA (ALIKO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €1.14 versus a price of €1.41, about 19% lower (overvalued).
What is the fair value of ALIKO?
Our estimate for Ikonisys SA is €1.14 (as of Nov 10, 2026), built from audited fundamentals. The current price: €1.41.
What is the quality score of ALIKO?
Ikonisys SA has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ikonisys SA (ALIKO)?
Our calculated price target is the estimate of €1.14 (as of Nov 10, 2026). Cautious scenario €0.8600, optimistic scenario €1.43. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ikonisys SA stock forecast for 2026?
Our estimate puts fair value at €1.14, about 19% lower versus a price of €1.41 (overvalued). Cautious scenario €0.8600, optimistic scenario €1.43. The calculation is refreshed regularly with new filings.
What is the revenue of Ikonisys SA (ALIKO)?
Ikonisys SA reported trailing-twelve-month revenue of about €1.6M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Ikonisys SA (ALIKO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ikonisys SA it is €1.14 per share (as of Nov 10, 2026), against a price of €1.41.
Is Ikonisys SA stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ALIKO trades above its calculated fair value: price €1.41, fair value €1.14, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALIKO?
No. The price is what the market pays today (€1.41); the fair value is what the company's own numbers justify (€1.14). For Ikonisys SA the two are €0.2700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ikonisys SA worth?
The market values Ikonisys SA at about €22.3M (market capitalisation, as of Nov 10, 2026). Per share that is €1.41; our models calculate a fair value of €1.14 per share.
What do the bullish and bearish scenarios say about ALIKO?
Our models span a range for Ikonisys SA: cautious scenario €0.8600, base €1.14, optimistic €1.43 per share (as of Nov 10, 2026, price €1.41). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ikonisys SA (ALIKO)?
Balance-sheet figures for Ikonisys SA (as of Nov 10, 2026): return on equity −16.4%, debt of 0.07 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is ALIKO from its 52-week high?
Ikonisys SA trades at €1.41, about 17% below its 52-week high of €1.70 and 6% above the low of €1.33 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €1.14 is for.
Which stocks are comparable to Ikonisys SA?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ikonisys SA stock attractive at the current price?
The data as of Nov 10, 2026: price €1.41, calculated fair value €1.14 (−19%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ikonisys SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ikonisys SA (ALIKO)?
The closing price on Nov 10, 2026 was €1.41. Our estimate is €1.14, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ikonisys SA right now?
Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ikonisys SA

How large is the market capitalisation of Ikonisys SA (ALIKO)?
The market capitalisation of Ikonisys SA is €22.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ikonisys SA (ALIKO)?
The price-to-sales ratio of Ikonisys SA is 13.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ikonisys SA (ALIKO)?
Earnings per share at Ikonisys SA are €−0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Ikonisys SA (ALIKO)?
The return on equity (ROE) of Ikonisys SA is −16.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ikonisys SA (ALIKO)?
On an EBIT basis the return on assets of Ikonisys SA is −10.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ikonisys SA (ALIKO)?
The operating margin of Ikonisys SA is −342% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ikonisys SA (ALIKO)?
Revenue at Ikonisys SA is growing +23.2% versus a year earlier (3y avg +14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ikonisys SA (ALIKO) generate?
The free cash flow of Ikonisys SA is −€1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ikonisys SA (ALIKO) carry?
The net debt of Ikonisys SA is €2.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ikonisys SA in the live analysis

One click puts Ikonisys SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.